Recently FDA-approved, erdafitinib, a pan-FGFR (FGFR1-4) tyrosine kinase inhibitor (TKI), has shown efficacy in treating advanced bladder cancer and intermediate- and high-risk NMIBC by blocking tyrosine kinase signaling [67,68]. Here, FGFR1 is linked to urinary bladder cancer.